The new rapid test "GT CoV-Influ antigen test" makes it possible to simultaneously detect not only the SARS-CoV-2 virus in humans but also influenza A and B viruses. The development has successfully passed clinical trials. The first deliveries to clinics and laboratories are scheduled for August 2022.

The rapid test is carried out by the method of lateral flow test (LFT), which makes it possible to detect dangerous respiratory viruses already in the early stages of the disease by one oropharyngual/nasopharyngual swab. The rapid test has high sensitivity and specificity, making it a fast alternative to PCR testing.

Rapid testing can be used as part of screening examinations of patients with symptoms of a respiratory disease to differentiate coronavirus infection and influenza viruses from ordinary acute respiratory viral infections and acute respiratory infections.

This is important because respiratory diseases:

“The COVID-19 pandemic has shown that an important element in stopping its spread and reducing the risk of complications in patients, first of all, is high-quality diagnostics. Among respiratory diseases, not only coronavirus infection, but also influenza viruses are dangerous. The test system developed by us, based on the rapid method for detection of the antigen, makes it possible to quickly detect SARS-Cov-2 and influenza A, B viruses, ”says one of the developers, Denis Viktorov, Director of Science at TestGene, Candidate of Biological sciences. 

Advantages of the test system: